• OPEN AN ACCOUNT
Indian Indices
Sensex
82,031.81 -500.38
( -0.61%)
Global Indices
Nasdaq
50,652.56 -976.61
(-1.89%)
Dow Jones
7,328.13 -109.46
(-1.47%)
Hang Seng
59,089.01 228.58
(0.39%)
Nikkei 225
10,545.68 -144.19
(-1.35%)
Forex
USD-INR
93.96 -0.30
(-0.32%)
EUR-INR
103.45 -0.43
(-0.42%)
GBP-INR
123.99 -0.51
(-0.41%)
JPY-INR
0.59 0.00
(-0.20%)

EQUITY - MARKET SCREENER

Sun Pharmaceutical Industries Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524715
INE044A01036
97.3802066
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SUNPHARMA
128.53
448687.64
EPS(TTM)
Face Value()
Div & Yield %
14.55
1
0.86
 

Timken India posts nearly 17% decline in Q4 PAT
May 19,2026

Total operating expenses for the period under review were Rs 848.05 crore, up 15% YoY.

Accordingly, profit before tax in Q4 FY26 stood at Rs 212.03 crore in Q4 FY26, up by 2.8% from Rs 206.22 crore in Q4 FY25.

Current tax outgo for the March 2026 quarter was Rs 49.77 crore, up 217% YoY. deferred tax charge was Rs 3.96 crore in Q4 FY26 as against Rs 0.21 crore in Q4 FY25.

For FY26, the company has recorded net profit and revenue from operations of Rs 414.89 crore (down 10.2% YoY) and Rs 3,478.03 crore (up 21.3% YoY), respectively.

Timken India is engaged in the manufacturing, distribution, and sale of anti-friction bearings, components, accessories, and mechanical power transmission products for the customer base across different sectors. It also provided maintenance contracts and refurbishment services and industrial services.

The scrip advanced 0.81% to currently trade at Rs 3456.75 on the BSE.